Skip to main content
. 2022 Jan 20;12:1068. doi: 10.1038/s41598-022-05209-8

Table 1.

Baseline characteristics of the entire study population and subgroups of patients who received adjuvant trastuzumab and those who did not receive adjuvant trastuzumab.

Variables All patients
N = 91 (%)
Treatment group
N = 39 (%)
Control
N = 52 (%)
p value
Age (years) 61 (range 30–89) 57 (30–76) 65 (30–89) 0.02
Comorbid illness 44 (48) 18 (46) 26 (50) 0.83
History of a secondary cancer 16 (18) 6 (15) 10 (19) 0.78
ECOG performance status
0 77 (85) 31 (80) 46 (89) 0.25
1 14 (15) 9 (20) 6 (11)
Smoking history 41 (45) 20 (50) 21 (40) 0.39
Current smoker 8 (9) 5 (13) 3 (6) 0.28
Surgery
Lumpectomy 43 (47) 17 (44) 26 (50) 0.67
Mastectomy 37 (41) 14 (36) 23 (44) 0.51
Bilateral mastectomy 11 (21) 8 (21) 3 (6) 0.04
Node exam
Sentinel node 77 (85) 34 (87) 43 (83) 0.77
Complete nodal dissection 13 (14) 5 (13) 8 (15) 0.77
Size in mm (mean ±) 6.4 ± 2.7 7.8 ± 2.0 5.3 ± 2.6 < 0.0001
T status
Tmic 1 (1) 0 1 (2)
T1a 33 (36) 3 (8) 30 (58) < 0.0001
T1b 57 (63) 36 (92) 21 (40) < 0.0001
Gradea
I 14 (15) 6 (15) 8 (15) 1.0
II 42 (46) 14 (36) 28 (54) 0.13
III 34 (37) 18 (46) 16 (31) 0.18
Margin within 1 mm 8 (9) 3 (8) 5 (10) 1.0
Hormone receptor status
ER positive 60 (66) 27 (69) 33 (64) 0.65
PR positive 45 (50) 20 (51) 25 (48) 0.83
Adjuvant systemic therapy 65 (71) 39 (100) 26 (50) < 0.0001
Adjuvant chemotherapy 40 (44) 39 (100) 1 (2) < 0.0001
Adjuvant endocrine therapy 53 (58) 27 (69) 26 (50) 0.08
Adjuvant radiation therapy 52 (57) 26 (67) 26 (50) 0.13

aGrade was unknown in one patient in the treatment group. ECOG Eastern Cooperative Oncology Group.